In an AD mouse model, acute treatment with an ADAM10 inhibitor substantially lowered LRP1 brain shedding and increased the appearance of Aβ40 in the plasma, indicating enhanced Aβ transit from the brain to the periphery. Here, LRP1 is linked to Alzheimer disease.